Australian company Telix has announced that it will supply ILLUCIX for a Phase 3 study investigating the efficacy of Bayer's PBS-listed NUBEQA (darolutamide) plus androgen deprivation therapy in hormone-sensitive prostate cancer. …
Australian company to supply Bayer with Illuccix for prostate cancer study
May 9, 2023 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
Vitex opens $250 million pharmaceutical manufacturing facility in Western Sydney
July 6, 2026 - - Latest News -
Early clinical imaging shows Syntara candidate reduces brain inflammation in people at high risk of Parkinson’s
July 6, 2026 - - Australian Biotech -
Widespread use of statins narrows heart-risk gap between overweight and normal-weight adults
July 6, 2026 - - Latest News -
A performative change that still leaves the door open for a response to 'MFN' risk
July 6, 2026 - - Latest News -
New law proposes limiting trade minister's power over PBS concessions
July 6, 2026 - - Latest News -
The 'Dispatched' Podcast - Season 5, Episode 22
July 3, 2026 - - Podcast -
Is that a subtle but meaningful shift conceding the potential need for a response to global realities?
July 3, 2026 -